GT Apeiron Therapeutics, a Shanghai, China-based biotech company utilizing technologies for drug discovery, raised $27m in funding.
Backers included GT Healthcare Capital Partners and associated investors.
The company also entered into a drug discovery collaboration with Exscientia, which utilizes artificial intelligence for drug discovery. Working with Exscientia’ automated AI drug discovery platform and other emerging technologies, Apeiron aims to accelerate the development of novel drugs via new pathways to tackle high impact therapeutic targets, with an initial focus on oncology.
Launched in 2019 by a team with extensive drug discovery expertise, Apeiron intends to develop investigational medicines by harnessing artificial intelligence, which increases efficiency throughout the drug discovery process, from target selection, hit identification, lead optimization to pre-clinical studies and clinical trials.